On January 10, 2018, Zhejiang Chengyi Pharmaceutical Co., Ltd. and Fuli Real Estate officially held a signing ceremony and successfully settled in the Hongqiao Fuli Center. Yan Yiyi, Chairman of Chengyi Pharmaceutical, and Tian Kai, Marketing Director of East China and Deputy General Manager of Shanghai Company of Fuli Real Estate, attended the signing ceremony and took a group photo as a souvenir.
Strategic height of listed companies
Zhejiang Chengyi Pharmaceutical Co., Ltd. is a listed enterprise on the main board of the Shanghai Stock Exchange, with stock code (603811). Founded in 1966, the company has now become a national key high-tech pharmaceutical enterprise specializing in the production of injections, capsules, tablets, raw materials, and pharmaceutical intermediates. It is the "first stock" of the Wenzhou pharmaceutical industry listed on the main board of the Shanghai Stock Exchange.
Cheng Yi Pharmaceutical can produce over 60 varieties and nearly a hundred specifications of drugs. All products have passed the Chinese national GMP certification, and multiple products have passed the GMP certification of foreign regulations such as the US FDA, Australia TGA, and the EU EMEA, enjoying a high reputation in the domestic and international pharmaceutical industry.
The resource endowment of Hongqiao Business District meets the requirements of diversified development of enterprises and also puts them at a higher strategic height. The purchase of an office building by Sincere Pharmaceutical at Shanghai Hongqiao Fuli Center is an important step taken by the group to establish overseas institutions. According to the relevant person in charge of Chengyi Pharmaceutical, "As the headquarters of the group's marketing center, Chengyi Pharmaceutical will establish its own sales team at the Hongqiao Fuli Center office property." At the same time, the office property in Hongqiao will also become a window, building an important transit hub for enterprises to go global.
Asia Pacific Hub Integration with International
The entry of Cheng Yi Pharmaceutical into the Hongqiao Business District is a forward-looking development strategy of a giant enterprise.
As the earliest enterprise in the Zhejiang pharmaceutical industry to go global, in 2018, Cheng Yi Pharmaceutical will continue to explore the international market, "targeting the international market, developing new formulations, and continuously enhancing the core competitiveness of the enterprise at home and abroad
As a pharmaceutical company that is in line with international standards, Cheng Yi Pharmaceutical's entry into Hongqiao will help accelerate the internationalization of the enterprise. Located at the key node of the Yangtze River Delta city axis, Hongqiao Business District can not only serve as the bridgehead of Shanghai Unicom in the Yangtze River Delta, but also serve as a gateway to the Asia Pacific and the world. Relying on the two major advantages of the Hongqiao transportation hub and the National Convention and Exhibition Center, the Hongqiao Business District has strong strategic advantages in factor aggregation and domestic and international market linkage.
Headquarter Hot Land and Famous Enterprise Neighboring
With the entry of listed companies such as Roche, Shell, Red Star Macalline, and Alibaba, more than 1000 companies have settled in the core area of Hongqiao Business District. Global enterprises are entering one after another, with unparalleled advantages not only including talent highlands and capital highlands, but also a legal environment for business that is in line with international standards. Cheng Yi Pharmaceutical's entry into the Hongqiao Business District is to choose to work with Fortune Global 500 and industry leaders to discover new development opportunities at the forefront of China's economy.
Cheng Yi Pharmaceutical, as a professional research and development enterprise, is actively moving towards the path of marine medicine and biopharmaceuticals, and building a big health industry pattern. Professional and high-end talent resources are crucial for achieving a company's development strategy. In the Hongqiao Business District, leading enterprises in the industry have settled one after another, creating a strong industrial agglomeration effect and talent aggregation effect, providing more development opportunities for the pharmaceutical industry.
At the same time, Hongqiao Business District has strengthened its talent introduction services and further enhanced its talent advantage through a comprehensive talent introduction policy. It is reported that Xuhui Talent Apartment and Beizhai Road City's public rental housing have been completed, while actively promoting the pilot of full rental housing and further improving the regional housing system.
Flagship Cover Headquarters Business
As the headquarters business cover of Hongqiao Business District, Hongqiao Fuli Center is recognized by many well-known enterprises, including Chengyi Pharmaceutical, for its high-quality headquarters office and comprehensive business facilities. As of now, more than ten listed company headquarters and industry leading enterprises have been settled. As an operator of Hongqiao Business District, Hongqiao Fuli Center will work together with more industry leaders to create a better future.